Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CTSA | P10619 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591064 | 1.00 | SLC2A1 (0.47) | SLC2A1KCNH2CTSAPOLBTDP1 | |
| SCHEMBL592025 | 1.00 | SLC2A1 (0.47) | SLC2A1KCNH2CTSAPOLBTDP1 | |
| SCHEMBL590211 | 0.89 | KCNH2 (0.47) | SLC2A1KCNH2 | |
| SCHEMBL590212 | 0.89 | KCNH2 (0.47) | SLC2A1KCNH2 | |
| SCHEMBL592813 | 0.84 | KCNH2 (0.42) | SLC2A1KCNH2 | |
| SCHEMBL592812 | 0.84 | KCNH2 (0.42) | SLC2A1KCNH2 | |
| SCHEMBL5263979 | 0.84 | KCNH2 (0.48) | SLC2A1KCNH2 | |
| SCHEMBL3244345 | 0.83 | KCNH2 (0.50) | SLC2A1KCNH2 | |
| SCHEMBL591795 | 0.81 | KCNH2 (0.48) | SLC2A1KCNH2 | |
| SCHEMBL5253770 | 0.79 | KCNH2 (0.44) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114867-B2 | Oxazolidinone antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | OXA1L, XDH, CCNY | SLC2A1 3298/4885KCNH2 2218/4885CTSA 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.